Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flibanserin 100 mg Daily in Premenopausal Women with HSDD
NCT00996164Phase 3Completed
- Sponsor
- Sprout Pharmaceuticals
- Start
- Oct 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoactive sexual desire disorder (HSDD) comparing flibanserin 100 mg with Placebo (2 arms). Primary endpoints: Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain and Change From Baseline in the Satisfying Sexual Events Count From Baseline to 24 Weeks. Started Oct 2009; status: completed.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT00996164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996164.